View More Recent Stories

Jan 25, 2022 08:30AM ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications
Jan 25, 2022 08:30AM ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications
Jan 10, 2022 08:00AM ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
Jan 10, 2022 08:00AM ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
Jan 4, 2022 04:30PM ORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 13, 2021 04:17PM ORIC Pharmaceuticals Inc. (ORIC) Reports Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma
Dec 13, 2021 04:15PM ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
Dec 13, 2021 04:15PM ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
Dec 9, 2021 04:30PM ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma
Dec 9, 2021 04:30PM ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma
Nov 11, 2021 04:15PM ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 10, 2021 05:04PM ORIC Pharmaceuticals Inc. (ORIC) Appoints Angie You to its Board
Nov 10, 2021 04:56PM ORIC Pharmaceuticals (ORIC) Appoints Angie You, Ph.D., to its Board of Directors
Nov 10, 2021 04:15PM ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors
Nov 10, 2021 04:15PM ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors
Nov 8, 2021 04:05PM ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update
Nov 8, 2021 04:05PM ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update
Nov 4, 2021 09:00AM ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
Nov 4, 2021 09:00AM ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
Oct 7, 2021 08:55AM ORIC Pharmaceuticals Inc. (ORIC) Presents Early Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114
Oct 7, 2021 08:55AM ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC
Oct 7, 2021 08:55AM ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC
Sep 30, 2021 04:30PM ORIC Pharmaceuticals Announces Multiple Data Presentations at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Sep 30, 2021 04:30PM ORIC Pharmaceuticals Announces Multiple Data Presentations at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Sep 21, 2021 06:30AM ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
Sep 21, 2021 06:30AM ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
Sep 1, 2021 08:00AM ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Sep 1, 2021 08:00AM ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Aug 16, 2021 04:17PM ORIC Pharmaceuticals Inc. (ORIC) Appoints Steven L. Hoerter to its Board
Aug 16, 2021 04:15PM ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors
Aug 16, 2021 04:15PM ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors
Aug 10, 2021 04:05PM ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
Aug 10, 2021 04:05PM ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
Jun 28, 2021 08:08AM ORIC Pharmaceuticals Inc. (ORIC) Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
Jun 28, 2021 08:00AM ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
Jun 28, 2021 08:00AM ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
Jun 2, 2021 04:55PM ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel
Jun 2, 2021 04:55PM ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel
May 26, 2021 04:30PM ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
May 26, 2021 04:30PM ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
May 25, 2021 08:00AM ORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel
May 25, 2021 08:00AM ORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel
May 6, 2021 04:05PM ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
Apr 28, 2021 04:05PM ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting
Apr 28, 2021 04:05PM ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting
Mar 23, 2021 04:05PM ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
View More Recent Stories